Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report

BMC Endocrine Disorders

Case Report

Toshitsugu Sugimoto¹  Masahiro Yamamoto¹  Masakazu Notsu¹  Ayumu Takeno¹ 

[1] Internal Medicine 1, Shimane University Faculty of Medicine, 89-1, Enya-cho, 693-8501, Izumo, Shimane, Japan;

关键词: Growth hormone deficiency (GHD);    Non-alcoholic fatty liver disease (NAFLD);    Non-alcoholic steatohepatitis (NASH);    Receptor activator of nuclear factor-kappa B ligand (RANKL);    Denosumab;   

DOI  :  10.1186/s12902-016-0148-0

 received in 2016-08-25, accepted in 2016-11-18,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundGrowth hormone deficiency (GHD) is associated with non-alcoholic fatty liver disease (NAFLD). A recent animal study showed that hepatocyte-specific receptor activator of nuclear factor-kappa B (RANK) knockout mice had significantly lower liver fat content compared with control mice concomitant with a decrease in production of inflammatory cytokines such as tumor necrosis factor-α (TNF-α) from hepatocytes and kupffer cells. The role of anti-RANK ligand (RANKL) antibody for osteoporosis on hepatitis in patients with aGHD is still unknown.Case presentationA forty-seven-year-old female patient was referred to our hospital to investigate chronic hepatitis caused by unknown etiology. She had past history of craniopharyngioma treated with craniotomy and post-surgical radiotherapy. She was for the first time diagnosed as panhypopituitarism including growth hormone deficiency and osteoporosis by endocrine examinations and bone mineral densitometry, respectively. In addition, non-alcoholic steatohepatitis (NASH) was histologically confirmed by liver biopsy in this time. Sixty mg anti-RANKL antibody, which was subcutaneously injected to treat the osteoporosis every six months after replacement of 5 mg hydrocortisone and 30 μg oral desmopressin, rapidly decreased the levels of her liver enzymes (ALT and γGTP were 133 to 72 U/L and 284 to 99 U/L at 16 months after the beginning of the treatment, respectively). Additional amelioration of liver dysfunction was not observed after growth hormone replacement.ConclusionsThe clinical course of the present case suggested that RANKL-RANK signaling may be a key pathological mechanism in establishment or development of NAFLD or NASH in patients with panhypopituitarism including GHD.

【 授权许可】

CC BY   
© The Author(s). 2016